BONESUPPORT HOLDING AB (publ) – publishes Q3 2025 Interim report

"Solid growth and new clinical evidence pave the way for continued success." Torbjörn Sköld, CEO

JULY - SEPTEMBER 2025

• Net sales increased by 24 percent (34 percent at constant exchange rates) and amounted to SEK 294.1 million (237.5).
• The US segment (previously named North America) reported a sales growth of 28 percent (40 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 5 percent (7 percent at constant exchange rates).
• The gross margin amounted to 92.9 percent (92.9).
• The adjusted operating result¹ amounted to SEK 78.6 million (48.3). The reported operating result amounted to SEK 65.4 million (41.0).
• Earnings per share before and after dilution were SEK 0.52 (0.46)

JANUARY - SEPTEMBER 2025

• Net sales increased by 34 percent (41 percent at constant exchange rates) and amounted to SEK 862.1 million (641.7).
• The US segment reported a sales growth of 41 percent (49 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 8 percent (10 percent at constant exchange rates).
• The gross margin amounted to 92.6 percent (92.6).
• The adjusted operating result amounted to SEK 180.7 million (125.9). The reported operating result amounted to SEK 149.9 million (101.9).
• Earnings per share before dilution were SEK 1.49 (1.22)
• Earnings per share after dilution were SEK 1.47 (1.20).

EVENTS DURING THE QUARTER

• During August, the Company announced that CMS has approved NTAP within open trauma for CERAMENT® G, providing additional hospital reimbursement within Medicare starting October 1, 2025.
• During September, strong results were published from a study that has been conducted at Stellenbosch University in South Africa. The study has demonstrated that CERAMENT G and CERAMENT® V can deliver the same excellent results for trauma patients with infection, in a developing market, as previously shown in studies at, among others, the Oxford Bone Infection Unit, UK.
• During September, positive results were published from a clinical study conducted at Charité in Berlin, demonstrating 100 percent infection referral for CERAMENT G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip.
• During September, Torbjörn Sköld started as CEO at BONESUPPORT. At the same time, former CEO Emil Billbäck transferred to a role as Senior Advisor.

EVENTS AFTER THE PERIOD

• Nothing to report.